

24<sup>th</sup> March, 2025

<p><b>To,</b> <b>Department of Corporate Services</b> <b>BSE Ltd.</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.</p> <p><b>Ref.: Scrip Code No. : 540701 (Equity)</b> <b>: 974556 and 975834 (Debt)</b></p>	<p><b>To,</b> <b>The Manager,</b> <b>Listing Department,</b> <b>National Stock Exchange of India Ltd.</b> “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051.</p> <p><b>Ref. : (i) Symbol – DCAL</b> <b>(ii) Series – EQ</b></p>
---	--

**SUB: PRESS RELEASE REGARDING COMPANY’S WHOLLY-OWNED SUBSIDIARY VIZ. CARBOGEN AMCIS SAS., RECEIVED CERTIFICATE OF GMP COMPLIANCE FROM NATIONAL AGENCY FOR THE SAFETY OF MEDICINE AND HEALTH PRODUCTS FOR ITS SAINT-BEAUZIRE SITE, FRANCE**

**REF.: i) DISCLOSURE UNDER REGULATIONS 30 AND 51 OF SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

**ii) OUR LETTER DATED 19<sup>TH</sup> MARCH, 2025 REGARDING REGULATIONS 30 AND 51: COMPANY’S WHOLLY-OWNED SUBSIDIARY VIZ. CARBOGEN AMCIS SAS., RECEIVED CERTIFICATE OF GMP COMPLIANCE FROM NATIONAL AGENCY FOR THE SAFETY OF MEDICINE AND HEALTH PRODUCTS FOR ITS SAINT-BEAUZIRE SITE, FRANCE**

Dear Sir,

In furtherance to our intimation dated 19<sup>th</sup> March, 2025, pleased find enclosed herewith Press Release regarding the Company’s wholly owned subsidiary namely CARBOGEN AMCIS SAS Secures GMP Certification After Successful ANSM Inspection for its Aseptic Drug Product Manufacturing Site viz. Saint-Beauzire Site, France from “National Agency for the safety of medicine and health products” (ANSM).



Dishman Carbogen Amcis Ltd  
Dishman Corporate House  
Iscon-Bopal Road, Ambli,  
Ahmedabad - 380058  
Gujarat, India  
CIN: L74900GJ2007PLC051338

+91 27 1742 0102  
dishman@dishmangroup.com  
www.imdcal.com



Kindly take this on your record.

Thanking you.

Yours faithfully,  
**For, Dishman Carbogen Amcis Limited**

**Shrima Dave**  
**Company Secretary**

## PRESS RELEASE

---

### **The Company announces that its subsidiaries, CARBOGEN AMCIS SAS Secures GMP Certification After Successful ANSM Inspection for its Aseptic Drug Product Manufacturing Site**

Ahmedabad, India (March 24, 2025) — Switzerland-based CARBOGEN AMCIS SAS, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, is pleased to announce the successful completion of the first inspection by the French regulatory authority, ANSM (National Agency for the safety of medicine and health products), at its state-of-the-art sterile drug product manufacturing site in Saint-Beauzire, France.

The inspection, conducted from January, 20th to January, 24th, follows the site's opening in February 2023. This is the first inspection of a routine process by ANSM to ensure compliance with Good Manufacturing Practices (GMP). As a result, CARBOGEN AMCIS SAS has been granted a GMP certificate for the Saint-Beauzire facility on March 19<sup>th</sup>, 2025, marking a significant milestone in the site's successful start-up. The certificate allows for the manufacture and release of clinical and commercial sterile drug products. The site received authorization from the ANSM to manufacture, test and release drug products from February 2023 and since then has been working under this authorization with the first clinical batch released in January 2024.

"This achievement reflects our team's dedication and hard work" said Angie Stevens, Vice President, Drug Product Business Unit. "I am incredibly proud of the commitment and motivation every Saint-Beauzire employee shows. With this certification, we look forward to actively supporting our customers in bringing new drugs to market and shaping a bright future together."

#### **A State-of-the-Art Facility**

Opened in early 2023, the Saint-Beauzire facility represents a major investment by CARBOGEN AMCIS (60 million euros). It underscores the company's commitment to enhancing sterile drug product manufacturing capabilities. The 9,500m<sup>2</sup> site features two fully automated production lines for liquid and lyophilized drug products, supporting a wide range of therapeutic areas, including highly potent compounds and advanced therapies such as antibody-drug conjugates. The flexible and versatile setup is unique within Europe and fully compliant with the latest EU GMP Annex 1 standards for sterile medicinal products.

With over 15 years of expertise developing injectable and liquid pharmaceutical forms, CARBOGEN AMCIS SAS' Saint-Beauzire site provides tailored solutions for pre-clinical and clinical trials and small-scale commercial manufacturing. It also creates significant job opportunities, employing approximately 130 highly skilled professionals.

#### **A Growing Portfolio of Services**

"The successful ANSM inspection reaffirms CARBOGEN AMCIS as a reliable partner in the drug product manufacturing market," said Helen Caddy-Leach, Head of Business Development, Drug Product. "With our extensive expertise and a state-of-the-art GMP-certified facility, we are well-positioned to support customers' drug product projects with excellence."

This new site complements CARBOGEN AMCIS' existing capabilities as a renowned API manufacturer. "Having a cutting-edge facility dedicated to the development and manufacture sterile drug products, including to a commercial scale, strengthens our ability to offer comprehensive end-to-end services, from drug substance to drug product," said Stephan Fritschi, CEO of CARBOGEN AMCIS. "This integrated approach is a significant advantage in today's competitive pharmaceutical landscape and provides added value for our clients."

#### **Supporting Global Pharmaceutical Innovation**

CARBOGEN AMCIS' eight sites across Switzerland, France, the United Kingdom, China, and the Netherlands deliver cGMP-compliant, innovative technologies that enable pharmaceutical and biopharmaceutical companies to bring next-generation medicines to market. The Saint-Beauzire site completes the CARBOGEN AMCIS group portfolio and is integral to the company's production chain. The site plays a critical role in this mission by enhancing the group's capacity to develop and manufacture advanced sterile drug products.

➤ To learn more about our GMP certified site, watch our dedicated video:  
[CARBOGEN AMCIS Secures GMP Certification](#)

\*\*\*\*

CARBOGEN AMCIS ([www.carbogen-amcis.com](http://www.carbogen-amcis.com)) is a leading service provider offering a portfolio of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries across all stages of clinical development and product life cycle. Our integrated services and innovative chemistry solutions support timely and safe drug development, allowing customers to better optimize available resources. CARBOGEN AMCIS is a wholly owned subsidiary of Dishman Carbogen Amcis Limited, Ahmedabad, India.

Dishman Carbogen Amcis Limited ([www.imdcal.com](http://www.imdcal.com)) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Carbogen Amcis group improves its customers' businesses by providing a range of development and manufacturing solutions at locations in Europe, China and in India.